Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05903924 · ClinicalTrials.gov registry record · Phase 3
Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness
A Phase 3 study, sponsored by Vanda Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 316
- Enrollment target
NCT05903924: Completed Phase 3 study, sponsored by Vanda Pharmaceuticals.
NCT05903924 is a Phase 3 study that has completed, run by Vanda Pharmaceuticals. The registered enrollment target is 316 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (59% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05903924, a Phase 3 study, has completed, sponsored by Vanda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 316 participants
- Enrollment target
Study Summary
A multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy of tradipitant in participants affected by motion sickness during travel
Primary Outcome
Prevention of vomiting measured by Vomiting Assessment (VA) score. The VA is a 1-item questionnaire to objectively measure the incidence of emesis. Participants will indicate whether or not they have vomited.
Interventions
- DRUG Placebo
- DRUG Tradipitant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 316 participants |
| Start Date | 2023-09-09 |
| Est. Completion | 2024-04-24 |
| Phase | Phase 3 |
What the finished NCT05903924 record still lists
NCT05903924 is an interventional study that assigns participants to a tested intervention. The registered 316 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (59% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05903924 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05903924 about?
NCT05903924 is a clinical study titled "Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness". A multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy of tradipitant in participants affected by motion sickness during travel
What is the current status of trial NCT05903924?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 316 participants. The study started on 2023-09-09. Estimated completion is 2024-04-24.
What interventions are being tested in trial NCT05903924?
The interventions under investigation include: Placebo (DRUG), Tradipitant (DRUG).
Who is sponsoring clinical trial NCT05903924?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05903924's enrollment target sits among peer trials
316 1090th of 2000 higher than 909 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04256317 · 316 participants · Phase 2
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- NCT04787042 · 316 participants · Phase 1
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
- NCT04802759 · 316 participants · Phase 1
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
- NCT05464056 · 316 participants · NA
BUILT Family Lifestyle Program for Children with ADHD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI